Sai Parenterals IPO to Raise ₹409 Crore: Price, Dates, GMP

Introduction

Sai Parenterals Limited is set to enter the public market with its Initial Public Offering (IPO) scheduled to open on March 24, 2026. The pharmaceutical company aims to raise approximately ₹409 crore through this mainboard issue, which includes a combination of a fresh issue of shares and an offer for sale (OFS) by existing shareholders. The IPO will be open for subscription for four days, concluding on March 27, 2026.

Offer Structure and Size

The total issue size of the IPO is valued at up to ₹408.79 crore at the upper end of the price band. The public offer is structured with two components:

• A Fresh Issue of 72,70,408 equity shares, aiming to raise ₹285 crore. The proceeds from the fresh issue are typically used for company growth, debt repayment, or other corporate purposes outlined in the prospectus.
• An Offer for Sale (OFS) component, where existing shareholders will sell up to 31,57,880 equity shares, aggregating to ₹124 crore. In an OFS, the proceeds go to the selling shareholders, not the company. In total, the company will offer 1,04,28,288 equity shares to the public.

Price Band and Investment Details

Sai Parenterals has fixed the price band for its IPO at ₹372 to ₹392 per equity share. The face value of each share is ₹5. Investors can bid for shares in lots, with one lot comprising 38 shares. For retail investors, the minimum investment required is ₹14,896 for a single lot at the upper price band of ₹392. The investment requirements for other categories are as follows:

• Small Non-Institutional Investors (sNIIs): Minimum application is for 14 lots (532 shares), amounting to ₹2,08,544.
• Big Non-Institutional Investors (bNIIs): Minimum application is for 68 lots (2,584 shares), requiring an investment of ₹10,12,928.

Key IPO Timeline

The schedule for the Sai Parenterals IPO has been clearly laid out for investors. It is important to keep track of these dates to participate in the offering and subsequent processes.

Investor Allocation Quotas

The IPO has a structured allocation for different categories of investors. Not more than 50% of the net issue is reserved for Qualified Institutional Buyers (QIBs). A minimum of 15% is allocated for Non-Institutional Investors (NIIs), and at least 35% of the issue is reserved for Retail Individual Investors (RIIs). This allocation ensures participation from various investor segments.

Company Valuation and Financials

Based on the company's filings, the Diluted Earnings Per Share (EPS) for the financial year 2025 stands at ₹5.43. At the upper price band of ₹392, the Price-to-Earnings (P/E) ratio can be calculated to assess the valuation. The company operates in the pharmaceutical formulations and Contract Development and Manufacturing Organization (CDMO) services sector.

Grey Market Premium (GMP) Status

As of the days leading up to the IPO opening, the Grey Market Premium (GMP) for Sai Parenterals shares is reported to be ₹0. The GMP is an unofficial indicator of how the IPO might perform on its listing day. A GMP of zero suggests that the shares are trading at their issue price in the grey market, indicating a neutral sentiment and potentially a flat listing. However, it is important to note that GMP is not an official metric and can change rapidly based on market sentiment and subscription demand.

Listing and Registrar Information

The equity shares of Sai Parenterals Limited are proposed to be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The tentative listing date is set for April 2, 2026. The registrar for the IPO is Bigshare Services Private Limited, which will be responsible for the allotment process, refund processing, and crediting of shares to the demat accounts of successful applicants.

Conclusion

The Sai Parenterals IPO presents an opportunity for investors to participate in a pharmaceutical company with a presence in formulations and CDMO services. The offering aims to raise ₹409 crore to support its future activities and provide an exit for some existing shareholders. With the IPO opening on March 24, potential investors should evaluate the company's financials, industry outlook, and valuation against the issue price. The current neutral GMP suggests a cautious market sentiment, and the final subscription figures will provide a clearer indication of investor interest before the shares list on April 2, 2026.